53 results about "Drug-Coated Stents" patented technology

The inventors have found that both the drug dose and drug release profiles are significant factors for the safety and efficacy of drug coated stents. The inventors have identified optimum dosing and release kinetics for drug coated stents. In particular, the inventors have determined dosing and release kinetics that permit the delivery of the lowest effective drug dosage, thus enhancing patient safety and minimizing any side effects from the drug.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The present invention provides a system for treating a vascular condition, including a catheter, a stent having a stent framework coupled to the catheter, a radiopaque oxide coating substantially covering at least an outer perimeter portion of the stent framework, and an encapsulant coating disposed on the radiopaque oxide coating. A drug-coated stent with a radiopaque oxide coating and a method of manufacturing are also disclosed.

The present invention provides a system for treating a vascular condition, which includes a catheter; a stent coupled to the catheter, the stent including a stent framework; a phenoxy primer coating operably disposed on the stent framework; and a drug-polymer coating disposed on the phenoxy primer coating. The present invention also provides a drug-coated stent and a method of manufacturing a drug-coated stent.

A drug-coated stent and a method for fabricating the stent are disclosed. The stent has an originally flat pattern and connection points where the sides of the flat pattern are joined. The method includes the steps of a) cutting a stent pattern into a flat piece of metal thereby to produce a metal pattern, b) spraying the flat metal stent pattern with a polymer and a drug, c) deforming the metal pattern so as to cause two opposing sides to meet, and d) joining the two opposing sides at least at one point. Substantially no portion of the stent projects into the lumen of the stent when the stent is expanded against the internal wall of a blood vessel.

The present invention provides a system for packaging a drug coated stent, including a transport package body including an arcuate catheter guide and a catheter. The catheter has a drug coated stent disposed thereon to be received in the catheter guide. A sheath including at least one reduced thickness region therein to increase flexibility of the sheath is disposed on the catheter, which encloses the drug coated stent.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The present invention provides a drug-coated stent comprising a tubular flexible body having a wall with a web structure that is expandable from a contracted delivery configuration to deployed configuration. The web structure comprises a plurality of neighboring web patterns, where each web patterns is composed of adjoining webs, and the web patterns are interconnected by transition sections. Each adjoining web comprises a central section interposed between two lateral sections to form concave or convex configurations.

Provided herein is a coated coronary stent, comprising: a stent framework; heparin molecules attached to the stent framework; and a rapamycin-polymer coating wherein at least part of rapamycin is in crystalline form. In one embodiment, the rapamycin-polymer coating comprises one or more resorbable polymers.

The present invention provides a drug-coated stent comprising a tubular flexible body having a wall with a web structure that is expandable from a contracted delivery configuration to deployed configuration. The web structure comprises a plurality of neighboring web patterns, where each web patterns is composed of adjoining webs, and the web patterns are interconnected by connection elements. Each adjoining web comprises a central section interposed between two lateral sections to form concave or convex configurations.

A method for manufacturing a drug carrying stent includes applying at least a first therapeutic agent to at least an outer portion of a stent framework and applying a first magnesium coating on at least a first portion of the applied first therapeutic agent.

A process for preparing cardiovascular stent with a drug coating layer on its surface is disclosed. It includes the steps of: 1. pretreatment for the stent surface by plasma 2. dipping or spraying of the stent surface in routine method by hyperplasia proof drug and coating polymer containing solution The drug coated stent prepared by the present invention can endure long period washing by all kinds of stress and body fluid in the stent transportation and dilation process, with the coating layer not easy to falling off.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The present invention provides a multilayer-coated stent for controlled drug release, comprising: a first base layer formed on a stent support and made of poly(ethylene-co-vinylacetate) or polystyrene-ethylene-butylene rubber polymer; a second coating layer formed on the first base layer and made of a biocompatible or a bioabsorbable polymer and a drug component; and a third coating layer formed on the second coating layer and made of a biocompatible or a bioabsorbable polymer and a drug component different from the drug component of the second coating layer. The inventive stent can deliver a broad range of therapeutic substances for a long time and prevent the early rapid release of the drug components in blood. Also, unlike the existing drug-coated stents, the inventive stent includes two kinds of drugs complementary to each other, but can optimize the efficacy of the drugs by differentiating the control of drug release according to time.

A sheath for temporarily protecting the drug coating on the surface of a stent after being mounted on a delivery catheter until just before use. The sheath is configured so as to enable its inner diameter to be temporarily increased to facilitate unrestricted fitment about and removal from the stent. Its inner diameter in its relaxed state is selected to be slightly less that the outer diameter of the mounted stent so as to positively grasp the stent and prevent dislodgement.

An artificial stent and its preparation method. The artificial stent comprises a stent body and a coating on it. The artificial stent is characterized in that the coating comprises a drug-loaded layer containing silk fibroin and a drug. The drug-loaded layer has a microporous structure substantially consists of silk fibroin and loaded with the drug. The microporous structure is obtained by a method comprising: uniformly coating the surface of the stent body with a solution of silk fibroin, denaturing by heat or chemical reagents; soaking the stent with purified water; then freeze drying and warming-drying, so as to from a microporous structure of the coating; loading the drug into the micropores in the coating; and removing the stent and drying. Silk fibroin used to coat the stent is a natural bio-material with great bio-compatibility; an can be absorbed and metabolized slowly by human body without adverse side effects, overcoming certain adverse effects of conventional drug-coated stents.

The invention discloses a novel drug-coated stent. The novel drug-coated stent comprises a stent body and a drug coating applied to the stent body, wherein the drug coating comprises drug and a drug carrier, the drug contains a tissue factor pathway inhibitor which is TFPI-1or TFPI-2, and the mass ratio of the drug to the drug carrier is 1:(8-12). The drug further contains one or two of sirolimus drug, taxol drug and statin drug. The thickness of the drug coating is 100-230 microns. The novel drug-coated stent has the advantages that stent thrombosis incidence can be reduced, the rate of recurrence of infarction and fatality rate of patients can be reduced remarkably, and long-term prognosis can be improved; usage of antiplatelet drugs and anticoagulant drugs is reduced, and the occurrence rate of bleeding events is reduced; the tissue factor pathway inhibitor is tissue factor physiological inhibitor, has high blood compatibility and histocompatibility, and is free of toxic or side effect and has few influences on human body.